Skip to main content

Market Overview

UK-Based Start-Up Working On Next COVID-19 Vaccine Using Animal Feces: FT

Share:
UK-Based Start-Up Working On Next COVID-19 Vaccine Using Animal Feces: FT
  • DIOSynVax, a UK start-up, hopes genetic sequences of viruses discovered in animal feces will give vital clues for creating a vaccine to help prevent future pandemics, reports Financial Times.
  • The Cambridge university spinout is working on two vaccines that it believes will outlive the currently available Covid-19 jabs, including the one created by researchers at rival Oxford University. 
  • Jonathan Heeney first became interested in coronaviruses when he diagnosed them in cats and cheetahs during his studies.
  • “By looking at animals, we’re better able to protect ourselves from the next pandemic or the next virus that is likely to cause a disease,” he said. 
  • He said DIOSynVax uses the genomic sequences of coronaviruses in all species to identify their “Achilles heel.” Scientists use computational biology tools to locate regions of the virus that cannot change without killing itself. 
  • The Coalition for Epidemic Preparedness Innovations has invested up to $42 million in DIOSynVax.
  • It is partnering with German biotech Ethris to manufacture the vaccine. The company already has a Covid-19 vaccine in an early-stage clinical trial. It believes it will be better at tackling variants than the vaccines based on the variant discovered in Wuhan in late 2019.
  • Photo by Gerd Altman via Pixabay
 

Related Articles (AZN + AZNCF)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 Coronavirus DiagnosticsBiotech News Health Care Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com